Key Points
- CEO Emily Leproust sold 5,203 Twist Bioscience shares for approximately $922,908 at an average price of $177.38. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced her direct stake by 0.84% to 613,699 shares.
- Twist Bioscience reported quarterly revenue of $118.38 million, up 23.2% year over year, but posted an adjusted loss of $0.56 per share, missing analysts’ estimate of a $0.51 loss.
- Analyst sentiment remains a “Moderate Buy”, with eight Buy, two Hold and two Sell ratings; the consensus price target is $103, well below the stock’s reported $182.83 opening price.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 5,203 shares of the business's stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $177.38, for a total value of $922,908.14. Following the transaction, the chief executive officer directly owned 613,699 shares in the company, valued at $108,857,928.62. This trade represents a 0.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Twist Bioscience Stock Down 0.7%
Shares of NASDAQ:TWST opened at $182.83 on Friday. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $186.20. The stock has a market cap of $11.47 billion, a P/E ratio of -82.36 and a beta of 2.22. The business has a fifty day moving average of $126.89 and a two-hundred day moving average of $87.13. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analysts' expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm's revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.33 EPS. On average, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have commented on TWST. TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Barclays increased their price target on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an "overweight" rating in a research note on Wednesday, June 24th. BWS Financial restated a "sell" rating and set a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group upped their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $103.00.
Check Out Our Latest Stock Analysis on Twist Bioscience
Hedge Funds Weigh In On Twist Bioscience
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP acquired a new position in Twist Bioscience in the 2nd quarter valued at about $62,000. Trifecta Capital Advisors LLC acquired a new stake in shares of Twist Bioscience during the second quarter worth about $63,000. Western Wealth Management LLC acquired a new position in shares of Twist Bioscience in the first quarter valued at approximately $31,000. Strs Ohio purchased a new stake in Twist Bioscience during the 1st quarter worth approximately $33,000. Finally, GAMMA Investing LLC increased its stake in Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company's stock worth $97,000 after buying an additional 185 shares during the period.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.
Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.
Twist was founded in 2013 and is headquartered in South San Francisco, California.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
